Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Novo Nordisk A/S



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.3%. By the end of trading, Novo Nordisk A/S rose $1.24 (3.2%) to $39.67 on average volume. Throughout the day, 1,393,946 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1,536,900 shares. The stock ranged in a price between $39.42-$39.79 after having opened the day at $39.53 as compared to the previous trading day's close of $38.43. Other companies within the Drugs industry that increased today were:

Enanta Pharmaceuticals



), up 13.4%,

Idera Pharmaceuticals



), up 12.6%,

Ventrus Biosciences



), up 8.2% and

Tekmira Pharmaceuticals Corporation



), up 7.4%.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $86.7 billion and is part of the health care sector. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 1.1% year to date as of the close of trading on Thursday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Novo Nordisk A/S

as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front,




), down 17.9%,

CytRx Corporation



), down 13.0%,

Oramed Pharmaceuticals



), down 11.4% and

Bacterin International Holdings



), down 10.0% , were all laggards within the drugs industry with




) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.